drugset / Trial / NCT00932607

SUBLIVAC® Birch PROBE Study

NCT00932607 ↗

Phase 2 Completed 74 enrolled HAL Allergy
RandomizedParallel-groupSingle-blindTreatment

Summary

Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in subjects suffering from IgE mediated allergic complaints triggered by birch pollen.

Timeline

Start
2009-07
Primary completion
2010-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject SUBLIVAC Birch Unknown 5 unknown Other
Subject Staloral Birch Unknown 4 unknown Other